ECOR Overview

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.

Wall Street analysts forecast ECOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ECOR is15.00 USD with a low forecast of 12.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

electroCore, Inc. revenue for the last quarter amounts to 9.58M USD, increased 42.64

electroCore, Inc.. EPS for the last quarter amounts to -0.59 USD, increased 25.53

electroCore, Inc. (ECOR) has 83 emplpoyees as of May 26 2026.

Today ECOR has the market capitalization of 55.33M USD.